References
- Ujike H, Otani K, Nakatsuka M et al. Association study of gender identity disorder and sex hormone-related genes. Prog. Neuropsychopharmacol. Biol. Psychiatry33(7), 1241–1244 (2009).
- Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA et al.; Endocrine Society. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab.94(9), 3132–3154 (2009).
- Meriggiola C, Jannini E, Lenzi A, Maggi M, Manieri C. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline – commentary from a European perspective. Eur. J. Endocrinol. DOI: 10.1530/EJE-09-1091 (2010) (Epub ahead of print).
- Righini M, Perrier A, De Moerloose P, Bounameaux H. D-dimer for venous thromboembolism diagnosis: 20 years later. J. Thromb. Haemost.6(7), 1059–1071 (2008).
- Murad MH, Elamin MB, Garcia MZ et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin. Endocrinol. (Oxf.) DOI: 10.1111/j.1365-2265.2009.03625.x (2009) (Epub ahead of print).
- Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J. Clin. Endocrinol. Metab.93(1), 19–25 (2008).
- Trebay G. He’s Pregnant, You’re Speechless. NewYork Times, 22 June 2008.
- Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp. Clin. Endocrinol. Diabetes113(10), 586–592 (2005).
- Ott J, Kaufmann U, Bentz EK, Huber JC, Tempfer CB. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil. Steril.93(4), 1267–1272 (2010).
- Chekir C, Nakatsuka M, Kamada Y, Noguchi S, Sasaki A, Hiramatsu Y. Impaired uterine perfusion associated with metabolic disorders in women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand.84, 189–195 (2005).
- Inoue H, Nishida N, Ikeda N et al. The sudden and unexpected death of a female-to-male transsexual patient. J. Forensic Leg. Med.14(6), 382–386 (2007).
- Berra M, Armillotta F, D’Emidio L et al. Testosterone decreases adiponectin levels in female to male transsexuals. Asian J. Androl.8, 725–729 (2006).
- Emi Y, Adachi M, Sasaki A, Nakamura Y, Nakatsuka M. Increased arterial stiffness in female-to-male transsexuals treated with androgen. J. Obstet. Gynaecol. Res.34(5), 890–897 (2008).
- Bunck MC, Giltay EJ, Diamant M, Gooren LJ, Teerlink T. Differential effects of cross-sex hormonal treatment on plasma asymmetric dimethylarginine (ADMA) in healthy male-to-female and female-to-male transsexuals. Atherosclerosis206(1), 245–250 (2009).
- Wilson R, Spiers A, Ewan J, Johnson P, Jenkins C, Carr S. Effects of high dose oestrogen therapy on circulating inflammatory markers. Maturitas62(3), 281–286 (2009).
- Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin. Endocrinol. (Oxf.)72(1), 1–10 (2010).
Website
- The Harry Benjamin International Gender Dysphoria Association’s Standards of Care for Gender Identity Disorders, Sixth Version www.wpath.org/documents2/socv6.pdf